SEC Form 4 · accession 0001933414-26-000099
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Malcom Rodman
Officer — Chief Medical Officer
Period of report
Jul 13, 2026
Accepted (ET)
Jul 15, 2026 · 8:58 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 13, 2026 | M | 3,542 | $10.20 | A | 61,275 | D | |
| Common Stock | Jul 13, 2026 | M | 4,167 | $14.25 | A | 65,442 | D | |
| Common Stock | Jul 13, 2026 | M | 6,349 | $1.08 | A | 71,791 | D | |
| Common StockF2 | Jul 13, 2026 | S | 14,058 | $27.5798 | D | 57,733 | D | |
| Common StockF3 | Jul 15, 2026 | S | 6,349 | $26.6112 | D | 51,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4 | $10.20 | Jul 13, 2026 | M | 3,542 | D | — | Feb 13, 2035 | Common Stock | 3,542 | 109,792 | D |
| Stock OptionF5 | $14.25 | Jul 13, 2026 | M | 4,167 | D | — | Feb 13, 2034 | Common Stock | 4,167 | 79,167 | D |
| Stock OptionF5 | $1.08 | Jul 13, 2026 | M | 6,349 | D | — | Jul 11, 2032 | Common Stock | 6,349 | 0 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.965 to $27.750. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- F4The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
- F5The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.